Challenges in the classification of atrial fibrillation

Nature Reviews Cardiology

Volumn 7, Issue 8, 2010, Pages 451-460

  Lubitz, Steven A ^a   Benjamin, Emelia J ^b   Ruskin, Jeremy N ^a   Fuster, Valentin ^c   Ellinor, Patrick T ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b FRAMINGHAM HEART STUDY   (United States)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACCURACY; DISEASE CLASSIFICATION; DISEASE COURSE; HEALTH CARE COST; HEART ATRIUM FIBRILLATION; HUMAN; MORBIDITY; MORTALITY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROGNOSIS; PUBLIC HEALTH; QUALITY OF LIFE; REPRODUCIBILITY; REVIEW; RISK FACTOR; STROKE; ATRIAL FIBRILLATION; CLASSIFICATION; ELECTROCARDIOGRAPHY; HEART ATRIUM FUNCTION; HEART MUSCLE CONDUCTION SYSTEM; HEART RATE; NOMENCLATURE; PREDICTIVE VALUE; SEVERITY OF ILLNESS INDEX;

ATRIAL FIBRILLATION; ATRIAL FUNCTION; DISEASE PROGRESSION; ELECTROCARDIOGRAM PATTERN; HEART CONDUCTION SYSTEM; HEART RATE; HUMANS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; SEVERITY OF ILLNESS INDEX; TERMINOLOGY AS TOPIC; ELECTROCARDIOGRAPHY;

EID: 77955013931     PISSN: 17595002     EISSN: 17595010     Source Type: Journal    
DOI: 10.1038/nrcardio.2010.86     Document Type: Review

References (105)

1. Go, A. S. et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 285, 2370-2375 (2001).
2. Miyasaka, Y. et al. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation 114, 119-125 (2006).
3. Stewart, S. et al. Trends in hospital activity, morbidity and case fatality related to atrial fibrillation in Scotland, 1986-1996. Eur. Heart J. 22, 693-701 (2001).
4. Frost, L., Vestergaard, P., Mosekilde, L. & Mortensen, L. S. Trends in incidence and mortality in the hospital diagnosis of atrial fibrillation or flutter in Denmark, 1980-1999. Int. J. Cardiol. 103, 78-84 (2005).
5. Tsang, T. S. et al. The prevalence of atrial fibrillation in incident stroke cases and matched population controls in Rochester, Minnesota: changes over three decades. J. Am. Coll. Cardiol. 42, 93-100 (2003).
6. Humphries, K. H. et al. Population rates of hospitalization for atrial fibrillation/flutter in Canada. Can. J. Cardiol. 20, 869-876 (2004).
7. Wolf, P. A. et al. Secular trends in the prevalence of atrial fibrillation: The Framingham Study. Am. Heart J. 131, 790-795 (1996).
8. Wolf, P. A., Mitchell, J. B., Baker, C. S., Kannel, W. B. & D'Agostino, R. B. Impact of atrial fibrillation on mortality, stroke, and medical costs. Arch. Intern. Med. 158, 229-234 (1998).
9. Coyne, K. S. et al. Assessing the direct costs of treating nonvalvular atrial fibrillation in the United States. Value Health 9, 348-356 (2006).
10. Lee, W. C. et al. Direct treatment cost of atrial fibrillation in the elderly American population: a Medicare perspective. J. Med. Econ. 11, 281-298 (2008).
11. Garrey, W. E. The nature of fibrillary contraction of the heart; its relation to tissue mass and form. Am. J. Physiol. 33, 397-414 (1914).
12. European Heart Rhythm Association et al. ACC/ AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation-executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation). J. Am. Coll. Cardiol. 48, 854-906 (2006).
13. Wells, J. L. Jr et al. Characterization of atrial fibrillation in man: studies following open heart surgery. Pacing Clin. Electrophysiol. 1, 426-438 (1978).
14. Konings, K. T. et al. High-density mapping of electrically induced atrial fibrillation in humans. Circulation 89, 1665-1680 (1994).
15. Sopher, S. M. & Camm, A. J. Therapy for atrial fibrillation: control of the ventricular response and prevention of recurrence. Coron. Artery Dis. 6, 106-114 (1995).
16. Lévy, S., Novella, P., Ricard, P. & Paganelli, F. Paroxysmal atrial fibrillation: a need for classification. J. Cardiovasc. Electrophysiol. 6, 69-74 (1995).
17. Gallagher, M. M. & Camm, A. J. Classification of atrial fibrillation. Pacing Clin. Electrophysiol. 20, 1603-1605 (1997).
18. Lévy, S. et al. Atrial fibrillation: current knowledge and recommendations for management. Working Group on Arrhythmias of the European Society of Cardiology. Eur. Heart J. 19, 1294-1320 (1998).
19. Lévy, S. Classification system of atrial fibrillation. Curr. Opin. Cardiol. 15, 54-57 (2000).
20. Reynolds, M. R., Ellis, E. & Zimetbaum, P. Quality of life in atrial fibrillation: measurement tools and impact of interventions. J. Cardiovasc. Electrophysiol. 19, 762-768 (2008).
21. Lane, D. A. & Lip, G. Y. Quality of life in older people with atrial fibrillation. J. Interv. Card. Electrophysiol. 25, 37-42 (2009).
22. European Heart Rhythm Association (EHRA) et al. HRS/EHRA/ECAS expert Consensus Statement on catheter and surgical ablation of atrial fibrillation: recommendations for personnel, policy, procedures and follow-up. A report of the Heart Rhythm Society (HRS) Task Force on catheter and surgical ablation of atrial fibrillation. Heart Rhythm 4, 816-861 (2007).
23. Kopecky, S. L. et al. The natural history of lone atrial fibrillation. A population-based study over three decades. N. Engl. J. Med. 317, 669-674 (1987).
24. Fuster, V. et al. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation. A report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to develop guidelines for the management of patients with atrial fibrillation) developed in collaboration with the North American Society of Pacing and Electrophysiology. Eur. Heart J. 22, 1852-1923 (2001).
25. McNamara, R. L. et al. ACC/AHA key data elements and definitions for measuring the clinical management and outcomes of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Data Standards on Atrial Fibrillation). Circulation 109, 3223-3243 (2004).
26. Dorian, P. et al. Validation of a new simple scale to measure symptoms in atrial fibrillation: the Canadian Cardiovascular Society Severity in Atrial Fibrillation scale. Circ. Arrhythm. Electrophysiol. 2, 218-224 (2009).
27. Kempster, P. A., Gerraty, R. P. & Gates, P. C. Asymptomatic cerebral infarction in patients with chronic atrial fibrillation. Stroke 19, 955-957 (1988).
28. Strickberger, S. A. et al. Relationship between atrial tachyarrhythmias and symptoms. Heart Rhythm 2, 125-131 (2005).
29. Israel, C. W., Gronefeld, G., Ehrlich, J. R., Li, Y. G. & Hohnloser, S. H. Long-term risk of recurrent atrial fibrillation as documented by an implantable monitoring device: implications for optimal patient care. J. Am. Coll. Cardiol. 43, 47-52 (2004).
30. Roche, F. et al. Frequent and prolonged asymptomatic episodes of paroxysmal atrial fibrillation revealed by automatic long-term event recorders in patients with a negative 24-hour Holter. Pacing Clin. Electrophysiol. 25, 1587-1593 (2002).
31. Page, R. L., Wilkinson, W. E., Clair, W. K., McCarthy, E. A. & Pritchett, E. L. Asymptomatic arrhythmias in patients with symptomatic paroxysmal atrial fibrillation and paroxysmal supraventricular tachycardia. Circulation 89, 224-227 (1994).
32. Takahashi, N., Seki, A., Imataka, K. & Fujii, J. Clinical features of paroxysmal atrial fibrillation. An observation of 94 patients. Jpn Heart J. 22, 143-149 (1981).
33. Scardi, S. et al. Lone atrial fibrillation: prognostic differences between paroxysmal and chronic forms after 10 years of follow-up. Am. Heart J. 137, 686-691 (1999).
34. Al-Khatib, S. M., Wilkinson, W. E., Sanders, L. L., McCarthy, E. A. & Pritchett, E. L. Observations on the transition from intermittent to permanent atrial fibrillation. Am. Heart J. 140, 142-145 (2000).
35. Lévy, S. et al. Characterization of different subsets of atrial fibrillation in general practice in France: the ALFA study. The College of French Cardiologists. Circulation 99, 3028-3035 (1999).
36. Kerr, C. R. et al. Progression to chronic atrial fibrillation after the initial diagnosis of paroxysmal atrial fibrillation: results from the Canadian Registry of Atrial Fibrillation. Am. Heart J. 149, 489-496 (2005).
37. Jahangir, A. et al. Long-term progression and outcomes with aging in patients with lone atrial fibrillation: a 30-year follow-up study. Circulation 115, 3050-3056 (2007).
38. Pappone, C. et al. Atrial fibrillation progression and management: A 5-year prospective follow-up study. Heart Rhythm 5, 1501-1507 (2008).
39. Nieuwlaat, R. et al. Prognosis, disease progression, and treatment of atrial fibrillation patients during 1 year: follow-up of the Euro Heart Survey on atrial fibrillation. Eur. Heart J. 29, 1181-1189 (2008).
40. Tsang, T. S. et al. Obesity as a risk factor for the progression of paroxysmal to permanent atrial fibrillation: a longitudinal cohort study of 21 years. Eur. Heart J. 29, 2227-2233 (2008).
41. Keating, R. J. et al. Effect of atrial fibrillation pattern on survival in a community-based cohort. Am. J. Cardiol. 96, 1420-1424 (2005).
42. Ruigómez, A., Johansson, S., Wallander, M. A. & Garcia Rodriguez, L. A. Predictors and prognosis of paroxysmal atrial fibrillation in general practice in the UK. BMC Cardiovasc. Disord. 5, 20 (2005).
43. Davidson, E., Rotenberg, Z., Weinberger, I., Fuchs, J. & Agmon, J. Diagnosis and characteristics of lone atrial fibrillation. Chest 95, 1048-1050 (1989).
44. Kato, T., Yamashita, T., Sagara, K., Iinuma, H. & Fu, L. T. Progressive nature of paroxysmal atrial fibrillation. Observations from a 14-year follow-up study. Circ. J. 68, 568-572 (2004).
45. Petersen, P. & Godtfredsen, J. Embolic complications in paroxysmal atrial fibrillation. Stroke 17, 622-626 (1986).
46. Flaker, G. C., Fletcher, K. A., Rothbart, R. M., Halperin, J. L. & Hart, R. G. Clinical and echocardiographic features of intermittent atrial fibrillation that predict recurrent atrial fibrillation. Stroke Prevention in Atrial Fibrillation (SPAF) Investigators. Am. J. Cardiol. 76, 355-358 (1995).
47. Saksena, S., Hettrick, D. A., Koehler, J. L., Grammatico, A. & Padeletti, L. Progression of paroxysmal atrial fibrillation to persistent atrial fibrillation in patients with bradyarrhythmias. Am. Heart J. 154, 884-892 (2007).
48. de Vos, C. B. et al. Progression from paroxysmal to persistent atrial fibrillation clinical correlates and prognosis. J. Am. Coll. Cardiol. 55, 725-731 (2010).
49. Budeus, M. et al. Prediction of conversion from paroxysmal to permanent atrial fibrillation. Pacing Clin. Electrophysiol. 30, 243-252 (2007).
50. Wijffels, M. C., Kirchhof, C. J., Dorland, R. & Allessie, M. A. Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goats. Circulation 92, 1954-1968 (1995).
51. Todd, D. M. et al. Repetitive 4-week periods of atrial electrical remodeling promote stability of atrial fibrillation: time course of a second factor involved in the self-perpetuation of atrial fibrillation. Circulation 109, 1434-1439 (2004).
52. Ausma, J. et al. Structural changes of atrial myocardium due to sustained atrial fibrillation in the goat. Circulation 96, 3157-3163 (1997).
53. Van Wagoner, D. R. et al. Atrial L-type Ca2+ currents and human atrial fibrillation. Circ. Res. 85, 428-436 (1999).
54. Allessie, M. A. et al. Pathophysiology and prevention of atrial fibrillation. Circulation 103, 769-777 (2001).
55. Lafuente-Lafuente, C., Mouly, S., Longas- Tejero, M. A. & Bergmann, J. F. Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation. Cochrane Database of Systematic Reviews, Issue 5. Art. No.: CD005049. doi:10/1002/14651858. CD005049.pub2 (2007).
56. Fauchier, L. et al. Antiarrhythmic effect of statin therapy and atrial fibrillation a meta-analysis of randomized controlled trials. J. Am. Coll. Cardiol. 51, 828-835 (2008).
57. Noheria, A., Kumar, A., Wylie, J. V. Jr & Josephson, M. E. Catheter ablation vs antiarrhythmic drug therapy for atrial fibrillation: a systematic review. Arch. Intern. Med. 168, 581-586 (2008).
58. Healey, J. S. et al. Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a metaanalysis. J. Am. Coll. Cardiol. 45, 1832-1839 (2005).
59. GISSI-AF Investigators et al. Valsartan for prevention of recurrent atrial fibrillation. N. Engl. J. Med. 360, 1606-1617 (2009).
60. Stewart, S., Hart, C. L., Hole, D. J. & McMurray, J. J. A population-based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study. Am. J. Med. 113, 359-364 (2002).
61. Wolf, P. A., Abbott, R. D. & Kannel, W. B. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 22, 983-988 (1991).
62. Stroke Risk in Atrial Fibrillation Working Group. Comparison of 12 risk stratification schemes to predict stroke in patients with nonvalvular atrial fibrillation. Stroke 39, 1901-1910 (2008).
63. Hart, R. G. et al. Stroke with intermittent atrial fibrillation: incidence and predictors during aspirin therapy. Stroke Prevention in Atrial Fibrillation Investigators. J. Am. Coll. Cardiol. 35, 183-187 (2000).
64. Hohnloser, S. H. et al. Incidence of stroke in paroxysmal versus sustained atrial fibrillation in patients taking oral anticoagulation or combined antiplatelet therapy: an ACTIVE W Substudy. J. Am. Coll. Cardiol. 50, 2156-2161 (2007).
65. Friberg, L., Hammar, N. & Rosenqvist, M. Stroke in paroxysmal atrial fibrillation: report from the Stockholm Cohort of Atrial Fibrillation. Eur. Heart J. 31, 967-975 (2010).
66. Sage, J. I. & Van Uitert, R. L. Risk of recurrent stroke in patients with atrial fibrillation and non-valvular heart disease. Stroke 14, 537-540 (1983).
67. Roy, D., Marchand, E., Gagné, P., Chabot, M. & Cartier, R. Usefulness of anticoagulant therapy in the prevention of embolic complications of atrial fibrillation. Am. Heart J. 112, 1039-1043 (1986).
68. Cabin, H. S., Clubb, K. S., Hall, C., Perlmutter, R. A. & Feinstein, A. R. Risk for systemic embolization of atrial fibrillation without mitral stenosis. Am. J. Cardiol. 65, 1112-1116 (1990).
69. Moulton, A. W., Singer, D. E. & Haas, J. S. Risk factors for stroke in patients with nonrheumatic atrial fibrillation: a case-control study. Am. J. Med. 91, 156-161 (1991).
70. [No authors listed] Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch. Intern. Med. 154, 1449-1457 (1994).
71. Treseder, A. S., Sastry, B. S., Thomas, T. P., Yates, M. A. & Pathy, M. S. Atrial fibrillation and stroke in elderly hospitalized patients. Age Ageing 15, 89-92 (1986).
72. Botto, G. L. et al. Presence and duration of atrial fibrillation detected by continuous monitoring: crucial implications for the risk of thromboembolic events. J. Cardiovasc. Electrophysiol. 20, 241-248 (2009).
73. Glotzer, T. V. et al. The relationship between daily atrial tachyarrhythmia burden from implantable device diagnostics and stroke risk: The TRENDS study. Circ. Arrhythm. Electrophysiol. 2, 474-480 (2009).
74. Wang, T. J. et al. Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: the Framingham Heart Study. Circulation 107, 2920-2925 (2003).
75. Friberg, L., Hammar, N., Pettersson, H. & Rosenqvist, M. Increased mortality in paroxysmal atrial fibrillation: report from the Stockholm Cohort-Study of Atrial Fibrillation (SCAF). Eur. Heart J. 28, 2346-2353 (2007).
76. Brand, F. N., Abbott, R. D., Kannel, W. B. & Wolf, P. A. Characteristics and prognosis of lone atrial fibrillation. 30-year follow-up in the Framingham Study. JAMA 254, 3449-3453 (1985).
77. Lüderitz, B. & Jung, W. Quality of life in patients with atrial fibrillation. Arch. Intern. Med. 160, 1749-1757 (2000).
78. Thrall, G., Lane, D., Carroll, D. & Lip, G. Y. Quality of life in patients with atrial fibrillation: a systematic review. Am. J. Med. 119, 448.e1-448.e19 (2006).
79. Thrall, G., Lip, G. Y., Carroll, D. & Lane, D. Depression, anxiety, and quality of life in patients with atrial fibrillation. Chest 132, 1259-1264 (2007).
80. Lane, D. A., Langman, C. M., Lip, G. Y. & Nouwen, A. Illness perceptions, affective response, and health-related quality of life in patients with atrial fibrillation. J. Psychosom. Res. 66, 203-210 (2009).
81. Härdén, M. et al. Validity and reliability of a new, short symptom rating scale in patients with persistent atrial fibrillation. Health Qual. Life Outcomes 7, 65 (2009).
82. Dorian, P. et al. A novel, simple scale for assessing the symptom severity of atrial fibrillation at the bedside: the CCS-SAF scale. Can. J. Cardiol. 22, 383-386 (2006).
83. Bhargava, M. et al. Impact of type of atrial fibrillation and repeat catheter ablation on longterm freedom from atrial fibrillation: results from a multicenter study. Heart Rhythm 6, 1403-1412 (2009).
84. Hindricks, G. et al. Perception of atrial fibrillation before and after radiofrequency catheter ablation: relevance of asymptomatic arrhythmia recurrence. Circulation 112, 307-313 (2005).
85. Dittrich, H. C. et al. Echocardiographic and clinical predictors for outcome of elective cardioversion of atrial fibrillation. Am. J. Cardiol. 63, 193-197 (1989).
86. Nattel, S. New ideas about atrial fibrillation 50 years on. Nature 415, 219-226 (2002).
87. Roberts, J. D. & Gollob, M. H. Impact of genetic discoveries on the classification of lone atrial fibrillation. J. Am. Coll. Cardiol. 55, 705-712 (2010).
88. Hong, K., Bjerregaard, P., Gussak, I. & Brugada, R. Short QT syndrome and atrial fibrillation caused by mutation in KCNH2. J. Cardiovasc. Electrophysiol. 16, 394-396 (2005).
89. Coumel, P. Paroxysmal atrial fibrillation: a disorder of autonomic tone? Eur. Heart J. 15 (Suppl. A), 9-16 (1994). (Pubitemid 24158556)
90. Nabauer, M. et al. The Registry of the German Competence NETwork on Atrial Fibrillation: patient characteristics and initial management. Europace 11, 423-434 (2009).
91. Gramley, F. et al. Decreased plasminogen activator inhibitor and tissue metalloproteinase inhibitor expression may promote increased metalloproteinase activity with increasing duration of human atrial fibrillation. J. Cardiovasc. Electrophysiol. 18, 1076-1082 (2007).
92. Chung, M. K. et al. C-reactive protein elevation in patients with atrial arrhythmias: inflammatory mechanisms and persistence of atrial fibrillation. Circulation 104, 2886-2891 (2001).
93. Li-Saw-Hee, F. L., Blann, A. D., Gurney, D. & Lip, G. Y. Plasma von Willebrand factor, fibrinogen and soluble P-selectin levels in paroxysmal, persistent and permanent atrial fibrillation. Effects of cardioversion and return of left atrial function. Eur. Heart J. 22, 1741-1747 (2001).
94. Kamath, S., Chin, B. S., Blann, A. D. & Lip, G. Y. A study of platelet activation in paroxysmal, persistent and permanent atrial fibrillation. Blood Coagul. Fibrinolysis 13, 627-636 (2002). (Pubitemid 35256142)
95. Tziakas, D. N. et al. Circulating levels of collagen type I degradation marker depend on the type of atrial fibrillation. Europace 9, 589-596 (2007).
96. Freestone, B., Chong, A. Y., Nuttall, S., Blann, A. D. & Lip, G. Y. Soluble E-selectin, von Willebrand factor, soluble thrombomodulin, and total body nitrate/nitrite product as indices of endothelial damage/dysfunction in paroxysmal, persistent, and permanent atrial fibrillation. Chest 132, 1253-1258 (2007).
97. Gaita, F. et al. Different patterns of atrial activation in idiopathic atrial fibrillation: simultaneous multisite atrial mapping in patients with paroxysmal and chronic atrial fibrillation. J. Am. Coll. Cardiol. 37, 534-541 (2001).
98. Tada, H. et al. Prevalence and characteristics of continuous electrical activity in patients with paroxysmal and persistent atrial fibrillation. J. Cardiovasc. Electrophysiol. 19, 606-612 (2008).
99. Xi, Q., Sahakian, A. V., Frohlich, T. G., Ng, J. & Swiryn, S. Relationship between pattern of occurrence of atrial fibrillation and surface electrocardiographic fibrillatory wave characteristics. Heart Rhythm 1, 656-663 (2004).
100. Benjamin, E. J. et al. Variants in ZFHX3 are associated with atrial fibrillation in individuals of European ancestry. Nat. Genet. 41, 879-881 (2009).
101. Gudbjartsson, D. F. et al. Variants conferring risk of atrial fibrillation on chromosome 4q25. Nature 448, 353-357 (2007).
102. Gudbjartsson, D. F. et al. A sequence variant in ZFHX3 on 16q22 associates with atrial fibrillation and ischemic stroke. Nat. Genet. 41, 876-878 (2009).
103. Benjamin, E. J. et al. Prevention of atrial fibrillation: report from a National Heart, Lung, and Blood Institute workshop. Circulation 119, 606-618 (2009).
104. Fang, M. C. et al. Comparison of risk stratification schemes to predict thromboembolism in people with nonvalvular atrial fibrillation. J. Am. Coll. Cardiol. 51, 810-815 (2008).
105. Koide, Y. et al. Usefulness of P-wave dispersion in standard twelve-lead electrocardiography to predict transition from paroxysmal to persistent atrial fibrillation. Am. J. Cardiol. 102, 573-577 (2008).